Savara (NASDAQ:SVRA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Savara (NASDAQ:SVRA) from a hold rating to a sell rating in a research report report published on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Savara Trading Down 2.7%

Shares of NASDAQ SVRA opened at $4.65 on Friday. The company’s fifty day moving average is $5.35 and its 200-day moving average is $5.42. The stock has a market cap of $955.39 million, a price-to-earnings ratio of -8.02 and a beta of 0.20. Savara has a twelve month low of $3.34 and a twelve month high of $7.01. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Equities research analysts predict that Savara will post -0.61 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of hedge funds and other institutional investors have recently bought and sold shares of SVRA. Principal Financial Group Inc. acquired a new position in Savara during the 1st quarter worth approximately $57,000. Sequoia Financial Advisors LLC acquired a new position in Savara during the second quarter worth $69,000. E Fund Management Co. Ltd. acquired a new position in Savara during the second quarter worth $77,000. Sanctuary Advisors LLC bought a new position in Savara in the second quarter valued at $87,000. Finally, Inceptionr LLC acquired a new stake in Savara in the 1st quarter valued at $84,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.